EGFR and esophageal squamous cell carcinoma: These discoveries have illuminated novel molecular mechanisms underlying ESCC progression mediated by hypoxic and EGFR pathways, thereby offering valuable insights for the development of innovative therapeutic targets and prognostic markers.